Skip to main content
Erschienen in: The Journal of Headache and Pain 1/2014

Open Access 01.12.2014 | Meeting abstract

EHMTI-0364. Non-invasive vagus nerve stimulation using gammacore® for prevention and acute treatment of chronic cluster headache: report from the randomized phase of the preva study

verfasst von: C Gaul, H Diener, K Solbach, N Silver, A Straube, D Magis, U Reuter, A Andersson, EJ Liebler

Erschienen in: The Journal of Headache and Pain | Sonderheft 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Introduction

Cluster headache (CH) is a painful and debilitating disorder for which non-invasive vagus nerve stimulation (nVNS) may be a treatment option.

Aim

Compare the efficacy of gammaCore®, a handheld nVNS device, with the standard of care (SoC) in chronic CH subjects in the randomized phase of the Prevention and Acute (PREVA) Treatment of Chronic Cluster Headache study.

Methods

PREVA was a multicenter study comprised of 3 phases: 2-week run-in, 4-week randomized (1:1; nVNS vs SoC), and 4-week extension. Subjects randomized to nVNS delivered stimulations prophylactically twice daily (mandatory) and optionally for the rescue treatment of CH attack. The primary efficacy end point was the reduction in number of CH attacks/week during the last 2 weeks of the randomized phase versus the run-in phase. Additional end points included the proportion of subjects with >50% reduction in CH attacks/week (response rate) and rescue medication use; safety was assessed by monitoring the frequency of adverse events.

Results

Ninety-seven subjects were randomized; data from 93 subjects (n=45 nVNS; n=48 SoC) were included in the intention-to-treat population. Number of CH attacks/week was significantly reduced in subjects treated with nVNS compared with patients treated with SoC only (-7.6 vs -2.0; P=.002). Further, significantly more nVNS- than SoC-treated subjects were considered treatment responders (34.4% vs 7.1%; P=.003). nVNS was associated with less use of rescue medications and demonstrated a favorable safety/tolerability profile.

Conclusion

Prophylactic treatment of chronic CH with nVNS is safe and, compared with SoC, reduces frequency of CH attacks/week. Sham-controlled studies are warranted and underway to confirm these data.
Abstract submitted on behalf of the PREVA Study Investigators.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://​creativecommons.​org/​licenses/​by/​4.​0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Metadaten
Titel
EHMTI-0364. Non-invasive vagus nerve stimulation using gammacore® for prevention and acute treatment of chronic cluster headache: report from the randomized phase of the preva study
verfasst von
C Gaul
H Diener
K Solbach
N Silver
A Straube
D Magis
U Reuter
A Andersson
EJ Liebler
Publikationsdatum
01.12.2014
Verlag
Springer Milan
Erschienen in
The Journal of Headache and Pain / Ausgabe Sonderheft 1/2014
Print ISSN: 1129-2369
Elektronische ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-15-S1-I7

Weitere Artikel der Sonderheft 1/2014

The Journal of Headache and Pain 1/2014 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.